Latest filing published 05 Apr 2022 for Zentalis Pharmaceuticals, Inc., €375k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +48.9%Entry US$50.90 · Close at T+365 US$75.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Anthony Y. Sun: trading record in brief
Anthony Y. Sun is a declared insider at 3 companies (chief executive); the most frequent names are Zentalis Pharmaceuticals, Inc., Aravive, Inc. and Hyperion Defi, Inc. Over a trading history stretching from 26 March 2014 to 5 April 2022, the count stands at 133 filings.
Market trades split into 3 purchases (€3.2M) and 106 sales (€27.8M). On balance, insiders were net sellers of €24.7M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 11 share grants. So far in 2022, the count stands at no purchases and 25 sales.
In size, the median ticket on the buying side is €912k.
The record was last updated on 5 April 2022 with an open-market sale (€375k) in Zentalis Pharmaceuticals, Inc. The latest purchase dates back some time: it was published 2,174 days ago, on 25 November 2020. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Anthony Y. Sun
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 7,971 shares@ US$51.34Common StockSEC:0001725160-22-000068:1
- 2,500 shares@ US$52.11Common StockSEC:0001725160-22-000068:2
- 10,471 shares@ US$48.509.1% of flowCommon StockSEC:0001725160-22-000068:0
- 1,700 shares@ US$50.05Common StockSEC:0001725160-22-000055:1
- 9,771 shares@ US$50.11Common StockSEC:0001725160-22-000055:2
- 700 shares@ US$50.91Common StockSEC:0001725160-22-000055:3
- 8,771 shares@ US$49.74327.6% of flowCommon StockSEC:0001725160-22-000055:0
- 4,208 shares@ US$50.16Common StockSEC:0001725160-22-000031:1
- 525 shares@ US$50.75Common StockSEC:0001725160-22-000031:2
- 50,431 shares0Common StockSEC:0001725160-22-000031:0
- 3,419 shares@ US$57.63Common StockSEC:0001725160-22-000017:1
- 2,828 shares@ US$58.59Common StockSEC:0001725160-22-000017:2
- 8,128 shares@ US$57.87Common StockSEC:0001725160-22-000017:4
- 2,343 shares@ US$58.29Common StockSEC:0001725160-22-000017:5
- 100 shares@ US$59.310.0% of flowCommon StockSEC:0001725160-22-000017:3
- 4,124 shares@ US$56.80964.1% of flowCommon StockSEC:0001725160-22-000017:0
- 2,573 shares@ US$78.26Common StockSEC:0001725160-22-000006:1
- 1,125 shares@ US$79.18Common StockSEC:0001725160-22-000006:2
- 4,372 shares@ US$80.36Common StockSEC:0001725160-22-000006:3
- 1,108 shares@ US$81.14Common StockSEC:0001725160-22-000006:4
- 993 shares@ US$82.18Common StockSEC:0001725160-22-000006:5
- 300 shares@ US$83.89Common StockSEC:0001725160-22-000006:6
- 2,000 shares@ US$77.71Common StockSEC:0001725160-22-000006:7
- 6,871 shares@ US$78.76Common StockSEC:0001725160-22-000006:8
- 1,556 shares@ US$79.54Common StockSEC:0001725160-22-000006:9
25 of 131 declarations
